N@N

Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors

^{Published on 2010-12-14 03:41:29 - Market Wire}
 

ROCKVILLE, Md.--([ BUSINESS WIRE ])--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Colin Goddard, Ph.D., former Chief Executive Officer of OSI Pharmaceuticals, has been appointed to the HGS Board of Directors.

"Dr. Goddard will add a broad-based perspective to our board, drawing from over 25 years of leadership experience in the biopharmaceutical industry. We look forward to benefiting from his strategic insights as we continue our transition to becoming a fully commercialized organization."

aWe are honored to have Colin Goddard join our board at this critical time in our companya™s growth and development,a said H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences. aDr. Goddard will add a broad-based perspective to our board, drawing from over 25 years of leadership experience in the biopharmaceutical industry. We look forward to benefiting from his strategic insights as we continue our transition to becoming a fully commercialized organization.a

Dr. Goddard joined OSI Pharmaceuticals as a scientist in 1989, and advanced through a series of senior management positions with increasing responsibility in drug discovery, research and corporate operations before being named Chief Executive Officer in 1998. OSI was acquired by Astellas Pharma Inc. in June 2010. Dr. Goddard served as a director of OSI from 1998 and served as Chairman of the OSI Board from 2000 to 2002. He led the transition of OSI from a technology platform services company into a profitable fully integrated biopharmaceutical company. He was instrumental in the approval and launch of OSIa™s flagship product, Tarceva (erlotinib), and also led OSIa™s corporate development, acquisition and financing efforts, completing multiple major acquisitions and divestitures and raising over $1.5 billion in capital. Prior to joining OSI, Dr. Goddard spent four years at the National Cancer Institute in Bethesda, MD.

Dr. Goddard trained as a cancer pharmacologist in Birmingham, U.K. and received his Ph.D. from the University of Aston, Birmingham, U.K. He was honored as a D.Sc. by the State University of New York in 2003 and by Hofstra University in 2005. Dr. Goddard serves on the boards of Zelos Therapeutics, a private biotechnology company focused on osteoporosis, and Abilities!, one of the worlda™s foremost facilities for educating and training people with disabilities. He is a member of the American Association of Cancer Research.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

For more information about HGS, please visit the Companya™s web site at [ www.hgsi.com ]. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to [ medinfo@hgsi.com ] or by calling HGS at (877) 822-8472. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciencesa™ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciencesa™ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciencesa™ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciencesa™ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Companya™s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of todaya™s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.